LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (Nasdaq:CBRX) has signed an agreement with PharmaBio Development, Inc., an affiliate of Quintiles Transnational Corp., under which Columbia can extend its final royalty payment on sales of STRIANT® (testosterone buccal system) from November 2010 to November 2011. The final payment is estimated at approximately $16.4 million.
